These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27456062)

  • 41. Update on gene and stem cell therapy approaches for spinal muscular atrophy.
    Donnelly EM; Boulis NM
    Expert Opin Biol Ther; 2012 Nov; 12(11):1463-71. PubMed ID: 22849423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
    Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
    PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spinal muscular atrophy: from gene to therapy.
    Wirth B; Brichta L; Hahnen E
    Semin Pediatr Neurol; 2006 Jun; 13(2):121-31. PubMed ID: 17027862
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.
    Brichta L; Hofmann Y; Hahnen E; Siebzehnrubl FA; Raschke H; Blumcke I; Eyupoglu IY; Wirth B
    Hum Mol Genet; 2003 Oct; 12(19):2481-9. PubMed ID: 12915451
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy.
    Ratni H; Karp GM; Weetall M; Naryshkin NA; Paushkin SV; Chen KS; McCarthy KD; Qi H; Turpoff A; Woll MG; Zhang X; Zhang N; Yang T; Dakka A; Vazirani P; Zhao X; Pinard E; Green L; David-Pierson P; Tuerck D; Poirier A; Muster W; Kirchner S; Mueller L; Gerlach I; Metzger F
    J Med Chem; 2016 Jul; 59(13):6086-100. PubMed ID: 27299419
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice.
    Zhou H; Janghra N; Mitrpant C; Dickinson RL; Anthony K; Price L; Eperon IC; Wilton SD; Morgan J; Muntoni F
    Hum Gene Ther; 2013 Mar; 24(3):331-42. PubMed ID: 23339722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neurodevelopmental consequences of Smn depletion in a mouse model of spinal muscular atrophy.
    Liu H; Shafey D; Moores JN; Kothary R
    J Neurosci Res; 2010 Jan; 88(1):111-22. PubMed ID: 19642194
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy.
    Nlend Nlend R; Meyer K; Schümperli D
    RNA Biol; 2010; 7(4):430-40. PubMed ID: 20523126
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of a single vector system that enhances trans-splicing of SMN2 transcripts.
    Coady TH; Baughan TD; Shababi M; Passini MA; Lorson CL
    PLoS One; 2008; 3(10):e3468. PubMed ID: 18941511
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spinal muscular atrophy: a new player joins the battle for SMN2 exon 7 splicing.
    Pedrotti S; Sette C
    Cell Cycle; 2010 Oct; 9(19):3874-9. PubMed ID: 20890126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy.
    Lesbordes JC; Cifuentes-Diaz C; Miroglio A; Joshi V; Bordet T; Kahn A; Melki J
    Hum Mol Genet; 2003 Jun; 12(11):1233-9. PubMed ID: 12761038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic activity of modified U1 core spliceosomal particles.
    Rogalska ME; Tajnik M; Licastro D; Bussani E; Camparini L; Mattioli C; Pagani F
    Nat Commun; 2016 Apr; 7():11168. PubMed ID: 27041075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice.
    Tsai LK; Chen CL; Ting CH; Lin-Chao S; Hwu WL; Dodge JC; Passini MA; Cheng SH
    Mol Ther; 2014 Aug; 22(8):1450-1459. PubMed ID: 24814151
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transplantation of gene-corrected motor neurons as a therapeutic strategy for spinal muscular atrophy.
    Meyer K; Miranda CJ; Kaspar BK
    Mol Ther; 2013 Mar; 21(3):502-3. PubMed ID: 23449105
    [No Abstract]   [Full Text] [Related]  

  • 55. U7 snRNA, a Small RNA with a Big Impact in Gene Therapy.
    Lesman D; Rodriguez Y; Rajakumar D; Wein N
    Hum Gene Ther; 2021 Nov; 32(21-22):1317-1329. PubMed ID: 34139889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. U7 snRNA: A tool for gene therapy.
    Gadgil A; Raczyńska KD
    J Gene Med; 2021 Apr; 23(4):e3321. PubMed ID: 33590603
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blood Flow to the Spleen is Altered in a Mouse Model of Spinal Muscular Atrophy.
    Deguise MO; Beauvais A; Schneider BL; Kothary R
    J Neuromuscul Dis; 2020; 7(3):315-322. PubMed ID: 32333548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Base editing-mediated splicing correction therapy for spinal muscular atrophy.
    Lin X; Chen H; Lu YQ; Hong S; Hu X; Gao Y; Lai LL; Li JJ; Wang Z; Ying W; Ma L; Wang N; Zuo E; Yang H; Chen WJ
    Cell Res; 2020 Jun; 30(6):548-550. PubMed ID: 32210360
    [No Abstract]   [Full Text] [Related]  

  • 59. Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy.
    Armbruster N; Lattanzi A; Jeavons M; Van Wittenberghe L; Gjata B; Marais T; Martin S; Vignaud A; Voit T; Mavilio F; Barkats M; Buj-Bello A
    Mol Ther Methods Clin Dev; 2016; 3():16060. PubMed ID: 27652289
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing.
    Friedmann T
    Gene Ther; 2017 Sep; 24(9):503-505. PubMed ID: 28639617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.